| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03584165 | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa | PHASE3 | ENROLLING BY_INVITATION | 330 | — | — | Jun 4, 2018 | Jun 4, 2026 | Jun 12, 2025 | 25 | United States, Brazil +7 |
| NCT03496012 | Efficacy and Safety of BIIB111 for the Treatment of Choroideremia | PHASE3 | COMPLETED | 169 | — | — | Dec 11, 2017 | Dec 1, 2020 | Dec 7, 2023 | 18 | United States, Canada +6 |
| NCT03507686 | A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 | PHASE2 | COMPLETED | 66 | — | — | Nov 29, 2017 | Jun 29, 2022 | Feb 23, 2024 | 6 | United States, France +1 |
BCVA was assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If \<20 letters are read at 4 meters, testing at 1 meter should be performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of participants with a ≥15 -letter improvement from baseline in BCVA at Month 12 was reported for both eyes.
BCVA was assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If \<20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eyes. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
IOP, the fluid pressure inside the eye was measured and reported in millimeters mercury (mmHg).
Slit lamp examinations of study eyes included examination of Cornea, Conjunctiva, Iris, Lens, and Anterior Segment.
Dilated Ophthalmoscopy examination of study eyes included examination of Vitreous, Macula, Peripheral retina, Choroid, and Optic nerve.
The following lens opacity grades are reported for categories 1-4: Nuclear Opalescence grade, Nuclear Color grade, Cortical Cataract grade, and Posterior Cataract grade. Opacification severity is graded on a decimal scale, scores can range from 0.1 (no opacity) to 6.9 (maximum opacity) for the Nuclear Opalescence and Nuclear Color grades; and scores can range from 0.1 (lens clear) to 5.9 (lens unclear) for the Cortical and Posterior Cataract grades. Category 1 includes values 1, 1.0 and 0.x, Category 2 includes values 2, 2.0 and 1.x, Category 3 includes values 3, 3.0 and 2.x, and Category 4 includes values 4, 4.0, 3.x and any values above 4. For each opacification type the higher grading scores indicate greater severity.
SD-OCT was used to assess change in foveal subfield thickness. The measurements were taken after dilation of the participant's pupil.
SD-OCT was used to assess change in total macular volume. The measurements were taken after dilation of the participant's pupil.
SD-OCT was used to assess change in central horizontal ellipsoid width. The measurements were taken after dilation of the participant's pupil.
SD-OCT was used to assess change in central ellipsoid area. The measurements were taken after dilation of the participant's pupil.
SD-OCT was used to assess change in square root of central ellipsoid area. The measurements were taken after dilation of the participant's pupil.
SD-OCT was used to assess change in choroidal thickness. The measurements were taken after dilation of the participant's pupil.
Fundus AF was used to assess the total area of preserved AF. Areas of preserved AF were identified as well-demarcated regions of relative hyper autofluorescence (hyper AF) compared with the background areas of surrounding atrophy.
Fundus AF was used to assess the square root of total area of preserved AF. Areas of preserved AF were identified as well-demarcated regions of relative hyper AF compared with the background areas of surrounding atrophy.
Fundus AF was used to assess the distance from foveal center to nearest border of preserved AF.
Number of participants with RPE hyperplasia are reported for severity grades: mild, moderate, severe.
Number of participants with retinal arteriolar narrowing are reported for severity grades: mild, moderate, severe.
Number of participants with retinal vessel sheathing are reported for severity grades: mild, moderate, severe.
Number of participants with optic atrophy/pallor are reported for severity grades: mild, moderate, severe.
Number of participants with optic disc swelling are reported for severity grades: mild, moderate, severe.
Microperimetry was conducted to assess retinal mean sensitivity within the macula. Retinal mean sensitivity to light was measured in decibels in multiple spots across the central and peripheral retina (entire visual field). Higher numbers (decibels) indicate higher retinal sensitivity.
Microperimetry was conducted to assess bivariate contour ellipse area 63%.
Microperimetry was conducted to assess bivariate contour ellipse area 95%.
Microperimetry was conducted to assess fixation losses (in percentage) which samples the optic nerve blind spot for positive responses.
An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug/surgical procedure, whether or not related to the investigational product or with the surgical procedure. TEAEs are defined as AEs starting on or after the day of the first surgery.
Tears (for both eyes- oculus dexter \[OD\] and oculus sinister \[OS\]), blood, urine and saliva samples were collected and tested using an appropriate assay for evidence of vector shedding. Participants with positive result for vector shredding post treatment are reported.
Participants with antibodies to the REP-1 transgenic product are reported.
Change from baseline in Systolic and diastolic blood pressures (BP) (millimeters of mercury \[mmHg\]) were reported.
Change from baseline in pulse rate (beats per minute) were reported.
| Arm | Type | Description |
|---|---|---|
| BIIB111 | EXPERIMENTAL | Participants previously treated with sub-retinal injection of BIIB111 in antecedent studies 273CH301 (NCT03496012) and 273CH203 (NCT03507686) will be enrolled. Participants previously treated with this same sub-retinal injection (rAAV2-REP1) in antecedent studies 20150371 (NCT02553135), Pro00028599 (NCT02077361), THOR-TUE-01 (NCT02671539), CHM09/01 (NCT01461213) and REGEN2015 (NCT02407678) will also be invited for enrollment. This is a follow-up study, investigational product was administered in the previous study. |
| BIIB112 | EXPERIMENTAL | Participants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled. This is a follow-up study, investigational product was administered in the previous study. |
| Untreated | NO_INTERVENTION | Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery. |
| BIIB111 High Dose | EXPERIMENTAL | Participants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy. |
| BIIB111 Low Dose | EXPERIMENTAL | Participants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy. |
| Untreated Control Group | NO_INTERVENTION | Participants will receive no sham surgery or study medication. |
| Name | Type | Description |
|---|---|---|
| BIIB111 | GENETIC | Administered as specified in the treatment arm. |
| BIIB112 | GENETIC | Administered as specified in the treatment arm. |
Key Inclusion Criteria: CHM Participants a. Have participated in and exited from an interventional study that investigated the safety and efficacy of a sub-retinal injection of BIIB111 for CHM. XLRP Participants a. Have received a sub-retinal injection of BIIB112 for XLRP and have exited an ante...